AzTrials
AzTrials

HPVNCT05681169

Schoolbased HPV-counselling and -Vaccination

A study testing School-based HPV-counselling and HPV-vaccination. in people with HPV and Complex Intervention, run by University of Aarhus at 1 site in Denmark.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study is designed as a non-randomized implementation study consisting of a user-centered school-based HPV-counselling and HPV-vaccination (HPVV) program. The aim is to improve HPVV coverage among children with ethnic minority background with minimum 10%-point in the intervention group. Read more about this study

Who is it for?
Ages 9 to 15 years
Conditions the study is for
HPV, Complex Intervention
What is being tested?
School-based HPV-counselling and HPV-vaccination.
Type of treatment
Vaccines
Could I receive a placebo?
No, everyone receives an active treatment
How many people
640 participants
Where
1 siteDenmark
Study dates
1 Aug 2022to 1 May 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 9 to 15 years
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Pupils in 4th, 5th and 6th grade at 5 schools with > 25% ethnic minority pupils, located in Aarhus, Denmark.
  • Age 9 - 15
  • For vaccination there will be mandatory parental consent

Who cannot join

  • Pupils from other schools or grades.
  • Exclusion criteria from vaccination will be medical history of severe anaphylactic reaction
  • Exclusion criteria from vaccination will be already initiated vaccination at general practitioner.

Trial locations and contacts

1 site in 1 country.

Denmark1 site
  • Anne Katrine Leonhard

    Aarhus, 8210

Other trials in Denmark

About this study

Official title: Schoolbased HPV-counselling and -Vaccination, a User-centred Intervention Targeting Children and Parents With Ethnic Minority Background

This study is designed as a non-randomized implementation study consisting of a user-centered school-based HPV-counselling and HPV-vaccination (HPVV) program. The aim is to improve HPVV coverage among children with ethnic minority background with minimum 10%-point in the intervention group.

Read the detailed description

Background:

Human Papillomavirus (HPV)-related cancers are considered the most preventive cancer form due to vaccination. HPVV in Denmark is a part of a national children vaccination programme. Despite free access to vaccination, children and adolescents with ethnic minority background attend substantially less to the vaccination programme than native Danes (79 vs 93%). Among some ethnic minority groups, the HPVV coverage is as low as 65%. Barriers among ethnic minorities towards vaccination for HPV are complex, thus insufficient understanding of HPV, emotional barriers to sexuality and cultural taboos are of significance. Schoolbased vaccination can improve HPVV uptake, and counselling supporting vaccination could be significant when targeting ethnic minority families.

Aim:

To test schoolbased HPV-counselling of parents and pupils together with schoolbased HPVV, in schools with more than 25% ethnic minority pupils, to improve HPVV coverage among children with ethnic minority background.

Hypotheses and aims:

Hypothesis 1: It is possible to improve participation in HPVV in Denmark when combining HPV-counselling with school-based vaccination compared to general practitioner-based vaccination.

  • Aim 1: To improve HPVV coverage among pupils attending schools with high concentration of non-native pupils. The investigators anticipate improving HPVV among ethnic minority pupils with at least 10%-point, and among native Danish pupils with at least 5%-point.

Hypothesis 2: It is possible to improve participation in HPVV among siblings to enrolled pupils, solely by improving HPV knowledge and awareness among their parents.

  • Aim 2: To improve HPVV coverage among siblings to enrolled pupils.

Hypothesis 3: A close cooperation with user-representatives will improve feasibility and implementation.

  • Aim 3: To develop and evaluate targeted counselling material concerning HPV and HPVV for parents and children with various ethnical backgrounds, eligible for national implementation.

Materials and methods:

Theoretical framework; The intervention is developed according to Complex Interventions Framework.Complex interventions contain several interacting components, and the guideline deals with development, assessment of feasibility, implementation, and evaluation. To operationalize the elements of the intervention, the investigators have applied a Logic Model, a graphic tool that illustrates the relationship between activities and intended outcome. By this, the investigators have combined theoretical knowledge and components of the intervention to accommodate to possible challenges in implementation.

Research design, study and control population; The intervention is conducted as a non-randomized implementation study. The intervention will be implemented schoolyear 2022/23. The intervention group consist of 640 children (11-13 years old) at 5 schools with > 25% ethnic minority pupils, located in Aarhus, Denmark. The control population will be approximately 2560 children comparable in age and regions with similar high concentration of ethnic minority populations.

Developed intervention;

The intervention consists of following core elements:

  1. Scholl-based parental HPV-counselling
  2. Scholl-based pupil HPV-counselling
  3. Scholl-based HPVV

Counselling-material have been developed according to existing knowledge of communication to ethnic minority parents regarding health issues. The investigators have developed mainly video and animation, which also helps to ensure methodological rigor. All developed material has been validated and adapted in cooperation with users-representatives. To support implementation, the counselling process is designed to demand only few school-professional resources.

Parental counselling; A. Oral presentation (10 min) explaining HPV and HPVV. It will be given by a health professional (Medical doctor, Phd-student) at first school-parent meeting, with ethnic minority ambassadors present.

  1. A simple printed presentation will be available in text and pictures (in Arabic, Turkish, Somali, English and Danish).
  2. The oral presentation will be available as a video texted in Arabic, Turkish, Somali, English and Danish. It will be accessible in a Facebook-group, solely for parents included in the intervention.

To all parents not attending the school-parent meeting, the investigators will send all written material and opportunity to submit for participation to both an online personal mailbox and by letter with a stamped return-envelope.

Pupil counselling; A. In a school-nurse setting, it will consist of an animation (3 min), which illustrates facts about HPV and vaccination. The storytelling is a conversation between two kids, diverse in gender and ethnicity and contains subjects as nervousness.

  1. The children will get a tote bag with a postcard, supporting the facts given in the animation and with an opportunity to submission by parents.
  2. The school-nurse will facilitate a conversation about vaccination and nervousness, using 5 question-cards.

School-based HPVV; First vaccination (HPVV1) will be offered after element 1-2 have been completed; the second (HPVV2) will be offered minimum five months later. Both will be given at pre-defined dates during school hours by qualified doctors and nurses. Dates will be visible on posters at school and reminder will be send to parents via school communication platform and text messages if this is selected by parents when submitting their child for vaccination.

Evaluation plan:

Quantitative and qualitative outcome, see outcome section.

Power calculation; The investigators have enrolled 5 schools, corresponding to approximately 640 children. 2560 children will be allocated to the control group (1:4 ratio). In both groups, roughly half of these children will be native Danes and the other half will be ethnic minorities. Estimating that minority pupils have a HPVV coverage of 65%, the study will be able to detect a difference of approximately 10 percent points in vaccination coverage between intervention and control group in the stratified analyses with a risk of type 1 error of 5% and type 2 error of 10% (power 90%).

Data sources and statistical analysis; The intervention group has been identified by The Municipality of Aarhus and the control group will be identified in the Danish Civil Registration System, as will parents and siblings to both intervention and control groups. Information on children's' ethnicity, and demographic and socioeconomic status on parents will be obtained from Statistics Denmark. Data on HPVV 1 and 2 will be collected from The Danish National Health Service Register through the Danish Health Data Authority.

Demographic and socioeconomic characteristics will be presented as numbers and proportions and differences between intervention and control groups tested using Pearson's chi-squared test. Regression analyses will be used to estimate the relative risk of not being vaccinated between intervention and control group. If differences between intervention and control group are identified, both crude and adjusted estimates will be presented with 95% confidence intervals. All analyses will be performed using STATA V.17.

Ethical Considerations; The project will be conducted in accordance with the Good Clinical Practice Guidelines, and is reported to the Data Protection Agency in Central Denmark Region (ref.nr. 761330, 1-16-02-494-21) and Central Denmark Region's Committees on Biomedical Research (1-10-72-274-21). Parents must submit their child for vaccination via written informed consent. HPVV will be offered at pre-defined dates during school hours and provided by qualified medical professionals according to existing guidelines. Each HPVV will be registered in The National Danish Childhood Vaccination Register. All data will be handled according to the EU's General Data Protection Regulation and all sensitive information will be handled safely by using REDcap. The municipality of Aarhus will provide personal data on intervention group in order to perform the invention and data processing agreement about disclosure has been concluded. Interviews will be executed in accordance with the Helsinki Declaration's rules on voluntariness and anonymity.

Collaborators and user-representatives:

From the Municipality of Aarhus, Department of Children and Youth, we have a consultant dedicated to the project. The project has been approved by political and administrative leaders, and these are close collaborators. Two school-nurses are user-representatives. "Neighbourhood mothers" is a national volunteer organization of minority women trained in health, family and the Danish society. They constitute a large group of user-representatives. 10 mothers and children with various ethnic and social background are user-representatives, as well as 2 health professionals with cultural insight. The non-governmental organization "Sex og Samfund" [sex and society] has contributed with consultation regarding counselling material.

Perspectives:

The perspectives of initiating school-based HPVV, is to create equal opportunities for participation in primary prevention from HPV-related cancer for all children living in Denmark. Results from this study may be used in future preventive interventions, and material can be used in future school-based vaccination programs.

The investigators expect that the intervention will contribute to minimize misinformation and taboos related to HPVV among ethnic minority families, causing the intervention to indirectly benefit the HPVV attendance of the family's other children, and contribute to reduce inequality in Danish health care.

This project is the first step in a larger project with an overall aim to improve HPV-related cervical cancer prevention among minority groups in Denmark, which takes place in a cross regional collaboration between Aarhus University Hospital, Odense University Hospital and Randers Regional Hospital.

Being tested
School-based HPV-counselling and HPV-vaccination.
Keywords
HPV, Vaccination program, Complex intervention, School-based, Patient involvement
Medical subject headings
Patient Participation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • School-based HPV-counselling and HPV-vaccination.Other

    1. Scholl-based parental HPV-counselling
    2. Scholl-based pupil HPV-counselling
    3. Scholl-based HPVV
Study groups in NCT05681169
Study groupRoleWhat they receive
School-based HPV-counselling and HPV-vaccinationExperimental640 pupils
Receives: Other: School-based HPV-counselling and HPV-vaccination.
Control groupNo interventionThe control population will be approximately 2560 children comparable in age and regions in Denmark with similar high concentration of ethnic minority populations.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. HPV-vaccination coverage in intervention group

    HPV coverage between intervention and control group as a total and stratified by ethnicity

    Measured: 1 year

Secondary outcomes (1)
  1. Estimated effect of HPV-counselling

    HPVV coverage for siblings of included pupils compared to an age- and area matched control group.

    Measured: 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Jan 2023
  2. Study start1 Aug 2022
  3. Primary completion1 Sep 2023
  4. Study completion1 May 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Non-randomised
Intervention model
Parallel groups
Model description
Non-randomized implementation study, ratio between intervention and control group will be 1:4.
Masking
None (open label)
Enrolment
640 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05681169
Sponsor's protocol ID
Schoolbased HPV-vaccination
Status last verified
Jun 2024
First submitted
19 Dec 2022
Last updated
20 Dec 2024
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: All of the results and experiences from the study are planned to be shared: * PhD-thesis with other researchers * Abstracts, posters and oral presentation at relevant conferences (EUROgin and IPVC (International Papillomavirus Conference) are planned) * Press and social media in Denmark * Oral presentations to organisations, the municipality of Aarhus and Neighbourhood Mothers. * Oral presentations to intervention interests, such as school nurses, teachers and school leaders.

Publications

  • Leonhard AK, Badre-Esfahani SK, Larsen MB, Petersen LK, Seibaek L. "Two shots for life. HPV-vaccination at your school". Co-creation of a complex intervention to reduce ethnic inequity in childhood HPV-vaccination in Denmark. PLoS One. 2025 Aug 20;20(8):e0323870. doi: 10.1371/journal.pone.0323870. eCollection 2025.

    PubMed 40833975

Questions about this trial

What is this clinical trial studying?

A study testing School-based HPV-counselling and HPV-vaccination. in people with HPV and Complex Intervention, run by University of Aarhus at 1 site in Denmark.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 20 Dec 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

HPV-vaccination coverage in intervention group (time frame: 1 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05681169, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Dec 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in